A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination with a Hypomethylating Agent after Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk AML, MDS, and MDS/MPN Overlap Syndromes